Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Beyond Routine Surveillance Imaging for Melanoma: Emerging Technologies for Detecting Early Recurrence and Guiding Clinical Management.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026

Same author

Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i><sup><i>V600E</i></sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.

JCO precision oncology·2026

Same author

Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.

Cancers·2026

Same author

Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study.

EClinicalMedicine·2025

Same author

Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2025

Same author

Management outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockade.

Journal of neuro-oncology·2025

Search research articles

Related Experiment Video

Updated: Mar 27, 2026

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Updates in Therapy for Advanced Melanoma.

Bhavana P Singh¹, April K S Salama²

¹Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA. bhavana.pendurthi@dm.duke.edu.

|January 20, 2016

Summary

Systemic therapy for cutaneous melanoma has advanced with targeted treatments like BRAF inhibitors and immune checkpoint inhibitors (CTLA-4, PD-1/PD-L1), improving patient outcomes.

Keywords:

BRAF CTLA-4 MEK PD-1 immunotherapy melanoma targeted therapy

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Mar 27, 2026

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

Oncology
Dermatology
Immunotherapy

Background:

Cutaneous melanoma is an aggressive skin cancer linked to significant mortality.
Advances in understanding melanoma genetics and immunology have driven therapeutic progress.

Purpose of the Study:

To review current systemic therapies for cutaneous melanoma.
To discuss the benefits and limitations of existing treatments.
To explore future directions in melanoma treatment.

Main Methods:

Literature review of recent advancements in melanoma systemic therapy.
Analysis of targeted therapies and immunotherapies.
Discussion of clinical trial outcomes and emerging agents.

Main Results:

Targeted therapies, including BRAF inhibitors, offer personalized treatment options.
Immune checkpoint inhibitors (CTLA-4, PD-1/PD-L1) have transformed melanoma management.
Multiple novel agents are under investigation for melanoma treatment.

Conclusions:

Systemic therapy for melanoma is increasingly sophisticated and multifaceted.
Current treatments provide significant clinical benefit but have limitations.
Future research holds promise for further improving melanoma patient survival.